RR
Rajesh Reddy Tummuru
About Rajesh Reddy Tummuru
Data last updated:
Rajesh Reddy Tummuru is a Director at Cytobiologics Private Limited (since 2021), Director at Promea Therapeutics Private Limited (since 2017) and Director at Bionutra Private Limited (since 2021), and holds 9 more current directorships. The companies operate in Healthcare, Real Estate and Construction and Financial Services. The 3 current companies with reported revenue have a combined latest revenue of ₹191 Cr; the largest is Cytobiologics Private Limited at ₹134 Cr (FY 2024). Earlier, Rajesh Reddy Tummuru was a Director at Previa Health Private Limited (2020–2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Cytobiologics Private Limited U24290TG2021PTC151278 | Director | 10 May 2021 | 2021 | ₹134 Cr (FY 2024) | Active |
 Promea Therapeutics Private Limited U24304TG2017PTC118617 | Director | 09 Oct 2017 | 2017 | ₹56.78 Cr (FY 2023) | Active |
| Bionutra Private Limited U15400TG2021PTC156681 | Director | 08 Nov 2021 | 2021 | ₹58.4 Lakh (FY 2023) | Active |
| Pro Immuna Therapeutics Private Limited U46497TS2026PTC219382 | Director | 14 Jul 2026 | 2026 | Active | |
| American Institute For Cellular Oncology Private Limited U46497TS2026PTC219384 | Director | 14 Jul 2026 | 2026 | Active | |
| Promea Novadx Private Limited U32500TS2026PTC210640 | Director | 03 Feb 2026 | 2026 | Active | |
| American Oncology Hospital Private Limited U86100TS2025PTC198606 | Director | 15 May 2025 | 2025 | Active | |
| Lekcon Farms Llp ACD-6118 | Designated Partner | 02 Feb 2024 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Previa Health Private Limited U85300TG2020PTC142646 | Director | 08 Aug 2020 | 2020 | ₹7.21 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Rajesh Reddy Tummuru
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rajesh Reddy Tummuru
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rajesh Reddy Tummuru
Rajesh Reddy Tummuru currently holds 12 directorships: Cytobiologics Private Limited (Director, since 10 May 2021, revenue ₹134 Cr (FY 2024)); Promea Therapeutics Private Limited (Director, since 09 Oct 2017, revenue ₹56.78 Cr (FY 2023)); Bionutra Private Limited (Director, since 08 Nov 2021, revenue ₹58.4 Lakh (FY 2023)); Pro Immuna Therapeutics Private Limited (Director, since 14 Jul 2026); American Institute For Cellular Oncology Private Limited (Director, since 14 Jul 2026); and 7 more.
Rajesh Reddy Tummuru was first appointed on 09 Oct 2017 as Director at Promea Therapeutics Private Limited. The most recent appointment on record is 14 Jul 2026 at American Institute For Cellular Oncology Private Limited.
The 3 current companies of Rajesh Reddy Tummuru that report revenue have a combined latest revenue of ₹191 Cr: Cytobiologics Private Limited ₹134 Cr (FY 2024); Promea Therapeutics Private Limited ₹56.78 Cr (FY 2023); Bionutra Private Limited ₹58.4 Lakh (FY 2023).
Rajesh Reddy Tummuru held 1 earlier board appointment: Previa Health Private Limited (Director, 08 Aug 2020 to 17 Feb 2025).
The current boards of Rajesh Reddy Tummuru's companies include Gopi Siva Krishna Lekkala (Cytobiologics Private Limited), Jeevan Sivakrishna Lekkala (Cytobiologics Private Limited), Pooja Aakanksha Gaddam (Promea Therapeutics Private Limited), Murali Krishna Reddy Tummuru (Pro Immuna Therapeutics Private Limited), Meena Tummuru (American Institute For Cellular Oncology Private Limited), Puneeth Babu Anne (American Institute For Cellular Oncology Private Limited), among others.